Tango Therapeutics (TNGX) reported second-quarter 2026 financial results and business highlights, including $1.0 billion in cash, cash equivalents and marketable securities as of June 30, 2026.
The company said initial Phase 1/2 data for vopimetostat plus daraxonrasib in MTAP-deleted, RAS-mutant pancreatic cancer showed a 92% objective response rate and a 90% six-month progression-free survival rate. Tango plans to present Phase 1/2 data from vopimetostat plus RAS(ON) inhibitors at the 2026 ESMO Congress.
- Collaboration revenue was $0 for the three months ended June 30, 2026, compared with $3.2 million a year earlier.
- Net loss was $55.3 million, or $0.37 per share, compared with a net loss of $38.9 million, or $0.35 per share, in the prior-year quarter.
- Research and development expenses were $37.2 million, compared with $32.8 million for the same period in 2025.
- General and administrative expenses were $22.6 million, compared with $11.3 million a year earlier.
- Tango appointed Fatma Ocak as Chief Commercialization Officer and named Robert Azelby Chairman of the Board.
- Upcoming milestones include finalizing the design of a Phase 3 randomized-controlled trial in front-line pancreatic cancer in the second half of 2026.
$TNGX Insider Trading Activity
$TNGX insiders have traded $TNGX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $TNGX stock by insiders over the last 6 months:
- ADAM CRYSTAL (President, R&D) has made 0 purchases and 13 sales selling 260,056 shares for an estimated $5,498,365.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TNGX Hedge Fund Activity
We have seen 121 institutional investors add shares of $TNGX stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 11,809,392 shares (+791.9%) to their portfolio in Q1 2026, for an estimated $247,052,480
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 10,298,485 shares (+410.1%) to their portfolio in Q1 2026, for an estimated $215,444,306
- FMR LLC added 7,038,371 shares (+245.4%) to their portfolio in Q1 2026, for an estimated $147,242,721
- PARADIGM BIOCAPITAL ADVISORS LP added 4,009,679 shares (+inf%) to their portfolio in Q1 2026, for an estimated $83,882,484
- FARALLON CAPITAL MANAGEMENT LLC removed 3,964,000 shares (-30.3%) from their portfolio in Q1 2026, for an estimated $82,926,880
- HOLOCENE ADVISORS, LP added 3,932,603 shares (+inf%) to their portfolio in Q1 2026, for an estimated $82,270,054
- BLACKROCK, INC. added 3,690,399 shares (+42.2%) to their portfolio in Q2 2026, for an estimated $115,361,872
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
